期刊文献+

来得时联合普通胰岛素强化治疗初发2型糖尿病疗效观察

Effect of Intensive Insulin Treatment with Insulin and Garline on Newly Diagnosed Type 2 Diabetic Mellitus
下载PDF
导出
摘要 目的:探讨早期胰岛素强化治疗初发2型糖尿病方案的优劣。方法:对2006年1月~2009年6月住院初发2型糖尿病患者90例进行回顾分析。空腹血糖(FBG)≥11.1mmol/L,HBA1C≥9.0%。根据当时采用的不同的胰岛素治疗方案,分成A、B、C三组。A组采用来得时联合普通胰岛素治疗,B组采用诺和灵N联合普通胰岛素治疗,C组采用预混胰岛素(诺和灵50R或30R)治疗。三组均在胰岛素治疗基础上,同时应用阿卡波糖、二甲双胍,不用促胰岛素分泌剂。比较三组降糖效果、血糖控制时间、胰岛素总量及低血糖发生率。结果:三组均显示明显的降糖效果,其中以A组来得时联合普通胰岛素治疗方案最优,血糖达标时间最短,胰岛素用量最少,低血糖发生率最低。结论:初发2型糖尿病患者早期胰岛素强化治疗中,来得时联合普通胰岛素能更有效地控制血糖水平,降低高糖毒性,减少胰岛素抵抗,促使胰岛β细胞功能恢复。 Objective:To investigate the effect of early intensive insuline treatment on newly diagnosed type 2 diabetic mellitus. Methods: A total of 90 patients with newly diagnosed type 2 diabetic mellitus in the hospital from January 2006 to June 2009 were retrospectively analyzed. The diagnosis was made with fasting blood glucose ≥ 11.1 mmol/L and HBA1C ≥ 9.0%. The patients were divided into 3 groups according to different drugs added to insulin: insulin garline injection( Group A) ,Novolin( Group B) ,and Novolin 50R or 30R( Group C). All groups were coadministered with acarbose and mefformin and no drug was used to promote insulin secretion. Blood glucose, time to glucose baseline, total dosage of insulin, and hypoglycemia were compared between the 3 groups. Results: The level of blood glucose was markedly reduced in all groups. Group A achieved the least time to reach normal blood glucose, the least dosage of insulin, and the lowest incidence of hypoglycemia. Conclusion: Intensive protocol with insulin and insulin garline injection has better effects on managing blood glucose, reducing insulin resistance, and promoting islet 13 cell function.
出处 《浙江中西医结合杂志》 2009年第12期727-729,共3页 Zhejiang Journal of Integrated Traditional Chinese and Western Medicine
关键词 初发2型糖尿病 来得时 胰岛素强化治疗 newly diagnosed type 2 diabetic mellitus insulin garline injection intensive insulin treatment
  • 相关文献

参考文献8

  • 1Poitout V, Robertson RP. Secondary beta-cell failure in type 2 diabetes-a convergence of glucotoxicity and lipotoxicity Endocrinology, 2002,143 : 339-342.
  • 2Colagiuri S, Cull CA, Holman RR, UKPDS Group. Are lower fasting plasma glucose levels at diagnosis of type 2 diabetes associated with improved outcomes? UK Prospective Diabetes Study 61. Diabetes Care,2002,25:1410-1417.
  • 3UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes( UKPDS 33 ). Lancet, 1998, 352 : 837-853.
  • 4刘娟,李延兵.早期胰岛素强化治疗在糖尿病治疗中的地位[J].新医学,2006,37(3):144-146. 被引量:34
  • 5程伟,严钟穗.长效胰岛素类似物的临床研究进展[J].国外医学(内分泌学分册),2003,23(4):237-239. 被引量:28
  • 6Lepore M, Pampanelli S, Fanell C, et al. Pharmaco-kinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine. NPH insulin and uhralente human insulin and continous subeutaneous infusion of ins. Diabetes ,2000,49(12) :2142-2148.
  • 7Edmond A, Ryan MD. Short2term intensive insulin therapy in newly diagnosed type 2 diatetes. Diabetes Care, 2004,27 (5) :1028-1032.
  • 8乔文颖,朱本章.短期强化胰岛素治疗对高血糖毒性作用的影响[J].中华内分泌代谢杂志,2003,19(6):453-454. 被引量:22

二级参考文献15

  • 1Ebeling P, Jansson P A, Smith U, et al. Strategies toward improved control during insulin lispro therapy in IDDM. Importance of basal insulin[J]. Diabetes Care, 1997,20 : 1287-1289.
  • 2Rosskamp R H, Park G. Long-acting insulin analogs[J].Diabetes Care,1999, 22(Suppl 2) :B109-B113.
  • 3Vajo Z, Fawcett J, Duckworth W C. Recombinant DNA technology in the treatment of diabetes [ J]. Endocr Rev, 2001,22:706-717.
  • 4McKeage K, Goa K L. Insulin Glargine [ J ]. Drugs, 2001,61 :1599-1624.
  • 5Heinemann L, Linkeschova R, Rave K. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo[J]. Diabetes Care, 2000,23 : 644-649.
  • 6Talaulicar M, Willms B, Rosskamp R. HOE901, ein neues insulin analog zur substitution des basalen insulin-bedarfs bei type 1 diabetes[ J ]. Diabetes Stoffwechsel, 1996,5 : 3-6.
  • 7Ratner R E, Hirsch I B, Neifing J L. Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes[J]. Diabetes Care ,2000,23 : 639-643.
  • 8Yki-Jarvinen H, Dressler A, Ziemen M. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes [ J ] .Diabetes Care,2000,23 : 1130-1136.
  • 9Hershon K, Blevins T, Donley D, et al. Lower fasting blood glucose(FBG) and less symptomatic hypoglycemia with QD insulin glargine(Lautus) compare to bid NPH insulin in subjects with type 1 diabetes[J]. Diabetes,2001,50( Suppl 2) :116-117.
  • 10Fonseca V, Bell D, Mecca T. Less symptomatic hypoglycemia with bedtime insulin glargine compared to bedtime NPH insulin in patients with type 2 diabetes [ J] . Diabetes, 2001,50(Suppl 2) : 112-113.

共引文献80

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部